Rejection, Transplant Completed Phase 4 Trials for Alemtuzumab (DB00087)

Also known as: Transplant Rejection / Transplant rejections / Graft Rejection

IndicationStatusPhase
DBCOND0030946 (Rejection, Transplant)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00331162Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas TransplantationPrevention